Source study found
Story checked
A 30-day benznidazole regimen offers safer Chagas disease treatment option (opens in a new tab)
news-medical.net · 2026-09-22
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
A 30-day benznidazole regimen offers safer Chagas disease treatment option
news-medical.net · 2026-09-22
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedA 30-day course of benznidazole taken once a day could offer people with chronic Trypanosoma cruzi infection a safer and more practical option than the current standard treatment, taken twice a day for 60 days.View evidenceHide evidence
As statedsafer and more practical; once daily for 30 days vs twice daily for 60 days
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 8Not checkedThe TESEO trial was co-led by The University of Texas at El Paso, the CEADES Foundation in Bolivia and the Barcelona Institute for Global Health (ISGlobal), and the results are reported in The Lancet Infectious Diseases.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 8Not checkedThe article says TESEO was the first randomized clinical trial to evaluate benznidazole and nifurtimox head-to-head under identical conditions, with sustained follow-up to detect parasites in the blood by PCR for three years.View evidenceHide evidence
As statedthree years of PCR follow-up
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 8Not checkedIn the phase 2b trial, 450 adults at three centers in Bolivia were randomly assigned to six groups testing three benznidazole regimens and three nifurtimox regimens over three years.View evidenceHide evidence
As stated450 adults; six treatment strategies; three years
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 8Not checkedOnly the 30-day benznidazole regimen significantly reduced side effects: 37% had a drug-related adverse event versus 60% on the standard regimen, and 83% completed treatment without interruption versus 60%.View evidenceHide evidence
As stated37% vs 60% adverse events; 83% vs 60% completion without interruption
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 6 of 8Not checkedThree years after treatment, the parasite remained undetectable in the blood of 94% of participants in the 30-day group and 95% in the standard group, which the article says demonstrated non-inferiority.View evidenceHide evidence
As stated94% vs 95% undetectable at three years
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 7 of 8Not checkedThe article says the 30-day regimen offered the best balance between benefits and harms of the six strategies tested, while the nifurtimox regimens were less effective overall.View evidenceHide evidence
As statedbest balance among six strategies; nifurtimox less effective overall
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 8 of 8Not checkedThe story says larger phase 3 trials are needed before the 30-day regimen can be incorporated into treatment guidelines, and patients should continue their prescribed treatment.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
The Lancet Infectious Diseases · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 16 candidate papers
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
The Lancet Infectious Diseases · 2026 · Crossref
Influence of Chagas Disease on the Pharmacokinetics of Benznidazole in the Dog Model.
ACS Pharmacology & Translational Science · 2026 · PubMed, Crossref
A RANDOMIZED TRIAL OF ACYCLOVIR FOR 7 DAYS OR 21 DAYS WITH AND WITHOUT PREDNISOLONE FOR TREATMENT OF ACUTE HERPES ZOSTER
The Pediatric Infectious Disease Journal · 1994 · Crossref
Chagas in Children Unmasked With Multimodality Imaging.
2026 · Europe PMC
Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.
PLoS Neglected Tropical Diseases · 2025 · PubMed
Duration of Antibiotic Therapy in Neonatal Gram-negative Bacterial Sepsis—10 Days Versus 14 Days
Pediatric Infectious Disease Journal · 2022 · Crossref
And 10 more candidates considered.